Unilever boss in U-turn on mega deals

Jope abandons takeover plans after botched £50bn GSK bid

UNILEVER’S boss has ruled out any blockbuster takeovers weeks after a botched attempt to buy a chunk of Glaxosmithkline for £50bn.

In a dramatic U-turn, Alan Jope said the Marmite and Hellmann’s owner was no longer pursuing megadeals as part of his strategy to move away from food, and instead focus on faster-growing health, beauty and hygiene brands.

The comments came less than four weeks after it emerged Unilever had seen three bids for the pharmaceutical group’s consumer health arm rejected, including a final offer worth £50bn.

At the time, Jope (pictured) said ‘major acquisitions’ were part of a new strategy, adding that the GSK offer was not ‘the only option’ and he would pursue other deals if it did not go through.

But announcing under-whelming annual results yesterday, he said: ‘We have engaged with shareholders in recent weeks and received a strong message that the evolution of our portfolio needs to be measured. We therefore do not intend to pursue major acquisitions in the foreseeable future.’

The £50bn bid for the GSK business – whose brands include Sensodyne and Panadol – was blasted by investors and wiped £10bn off the value of the company.

In a bid to placate shareholders yesterday, Jope announced plans to return £2.5bn to investors through a share buyback. He also upped the firm’s dividend by 3pc, meaning it will pay out £920m.

But the stock fell 1.3pc, or 49.5p, to 3779p, leaving the company worth £96.6bn.

The slide came as Unilever, which makes Dove, Wall’s ice cream and Domestos, warned profits will be hit as soaring inflation lands it with £3bn of extra costs this year.

It said sales would grow as much as 6.5pc in 2022, but much of this would be down to price rises rather than selling more products. And it warned the ‘very high’ inflation will knock as much as 2.4 percentage points off its profit margins.

It hopes a recently announced restructure, which involves axing 1,500 management jobs worldwide, will save £500m in the next two years.

Jefferies analyst Martin Deboo said the downgrade was ‘dramatic’ and compounded Unilever’s troubles after the failed GSK bid. He said: ‘We expect management credibility to come under further pressure.’

Unilever said turnover hit £44bn last year as sales rose 4.5pc. Profits were up 4.8pc to £7.3bn.

The results followed a turbulent month for Jope in which he has been criticised by top shareholders over his strategy.

A top 20 shareholder said Unilever chairman Nils Andersen should be removed from the board for allowing Jope to pursue the GSK takeover.

And another top shareholder – Fundsmith manager Terry Smith – blasted Jope for the GSK approach just a week after claiming Unilever had ‘lost the plot’ over its obsession with woke social issues.

Activist investor Nelson Peltz has also begun stalking the company, taking a stake through his New York-based fund Trian Partners. But Jope received a boost this week as the head of Unilever’s fourth biggest shareholder, Lindsell Train, said he was right to consider the GSK takeover.

Jope said Train’s comments reflect what shareholders have told him. But Bernstein analyst Bruno Monteyne said: ‘I don’t think that today’s results will change minds. Investors that were already asking for management change, are unlikely to change their mind.’